Core evidence proof of concept summary for axitinib in thyroid cancer

Outcome measure	Emerging evidence
Efficacy	Potential to use as monotherapy at a dose of 5 mg twice daily; stable disease achieved in 38% of patients and progression-free survival of 18.1 months
Response rates	Evidence of activity with overall response rates of 30%
Biomarker expression	Decreases levels of soluble VEGFR 2 and 3. Blood pressure elevation may correlate with response
Tolerability	Well tolerated, with hypertension, fatigue, and proteinuria as the most common grade 3 side effects

Abbreviations: VEGFR, vascular endothelial growth factor receptor.